Domov › Rak jajčnikov › Oklahoma › Oklahoma City
Klinične študije za Rak jajčnikov v Oklahoma City, OK
28 študij za Rak jajčnikov išče udeležence na lokacijah v Oklahoma City in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.
Uradno besedilo študije (angleško)
Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →
The Vanguard Study: Testing a New Way to Screen for Cancer
Vključevanje udeležencevVabljeni zdravi prostovoljci
- University of Oklahoma Health Sciences Center, Oklahoma City
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Vključevanje udeležencevFaza 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Vključevanje udeležencevFaza 1/2
- OU Health, Stephenson Cancer Center, Oklahoma City
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Vključevanje udeležencevFaza 1/2
- University of Oklahoma, Oklahoma City
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
Vključevanje udeležencevFaza 2
- OU Health - Stephenson Cancer Center /ID# 277656, Oklahoma City
Study of AVZO-021 in Patients With Advanced Solid Tumors
Vključevanje udeležencevFaza 1/2
- Avenzo Therapeutics Recruiting Site, Oklahoma City
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Vključevanje udeležencevFaza 1/2
- Stephenson Cancer Center, Oklahoma City
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Vključevanje udeležencevFaza 3
- University of Oklahoma Health Sciences Center, Stephenson Cancer Center, Oklahoma City
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Vključevanje udeležencevFaza 1/2
- University of Oklahoma, Oklahoma City
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Vključevanje udeležencevFaza 1/2
- OU Health Stephenson Cancer Center, Oklahoma City
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Vključevanje udeležencevFaza 3
- Oklahoma University Health Stephenson Cancer Center, Oklahoma City
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- OU Health Stephenson Cancer Center, Oklahoma City
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Vključevanje udeležencevFaza 1
- Normunity Investigational Site, Oklahoma City
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Vključevanje udeležencev
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
A Study of DM002 in Patients With Advanced Solid Tumors
Vključevanje udeležencevFaza 1/2
- University of Oklahoma Health Sciences Center, Oklahoma City
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Vključevanje udeležencevFaza 3
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Vključevanje udeležencevFaza 1/2
- University of Oklahoma - Health Sciences Center, Oklahoma City
Clinical Pre-screening Protocol for Ovarian Cancer
Vključevanje udeležencevOpazovalna študija
- OU Health Stephenson Cancer Center, Oklahoma City
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Vključevanje udeležencevFaza 1/2
- Stephenson Cancer Center, Oklahoma City
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Vključevanje udeležencevFaza 2/3
- University of Oklahoma Health Sciences Center, Oklahoma City
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Vključevanje udeležencevFaza 2
- University of Oklahoma, Oklahoma City
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- OU Health University of Oklahoma Medical Center, Oklahoma City
- Stephenson Cancer Center (chemo location), Oklahoma City
- University of Oklahoma Health Science Center, Oklahoma City
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Vključevanje udeležencevFaza 1/2
- Stephenson Cancer Center Oklahoma University Health, Oklahoma City
Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk Women
Vključevanje udeležencevVabljeni zdravi prostovoljci
- University of Oklahoma Health Sciences Center, Oklahoma City
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- Stephenson Cancer Center, Oklahoma City
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Vključevanje udeležencevFaza 1
- Dren Investigational Site, Oklahoma City
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
Vključevanje udeležencevFaza 2
- Stephenson Cancer Center at the University of Oklahoma, Oklahoma City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- Exelixis Clinical Site #13, Oklahoma City
Študije za Rak jajčnikov v drugih mestih
- Houston, TX89 študij
- New York City, NY69 študij
- Boston, MA61 študij
- Los Angeles, CA50 študij
- Nashville, TN49 študij
- Arlington, VA46 študij
- Philadelphia, PA44 študij
- Columbus, OH39 študij
- St. Louis, MO38 študij
- Chicago, IL36 študij
- San Antonio, TX31 študij
- Cleveland, OH30 študij
Druge študije v Oklahoma City
- Nemalicelični pljučni rak28 študij
- Rak endometrija25 študij
- Kolorektalni rak22 študij
- Rak prostate21 študij
- Rak pljuč19 študij
- Rak dojke17 študij
- Metastatski rak16 študij
- Rak (vse vrste)14 študij
- Akutna mieločna levkemija14 študij
- Ploščatocelični karcinom glave in vratu13 študij
- Rak mehurja11 študij
- Rak trebušne slinavke11 študij
Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.